A Phase 3 interventional study of Hypertonic saline solution in TBI Traumatic Brain Injury, sponsored by Nantes University Hospital. Recruiting at 25 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Nantes University Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Brain Injuries, Traumatic with a site in France — 23 open to participants now, 25 under way, 2 of them phase 3. Brain Injuries, Traumatic · France.
Among the 98 studies in Brain Injuries, Traumatic with a site in France, this one is the 2nd largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 18 of the 24 other live ones, and was the 95th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →23 of the 98 studies in Brain Injuries, Traumatic with a site in France are open now. Recruiting first, the newest first:
Pôle Saint Hélier · Sites in France
Ages 18–55 · Healthy volunteers
Direction Centrale du Service de Santé des Armées · Sites in France
Ages 18–65 · Healthy volunteers
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18–65 · Healthy volunteers
University Hospital Center of Martinique · Sites in France
Ages 18+
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 36 mo–71 mo
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 12 · Phase 4 5
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 760 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 55 across the 66 interventional studies, 172 across the 32 observational. Of the 56 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 98 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 7 studies filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
5 of the studies in Brain Injuries, Traumatic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06830291Direction Centrale du Service de Santé des ArméesValidation and Standardisation of a "Neuralix" Digital Ecological Battery | 2027-03 |
| NCT04534777Assistance Publique - Hôpitaux de ParisMultimodal Neuroprognostication in Disorders of Consciousness | 2027-05 |
| NCT05277519Institut National de la Santé Et de la Recherche Médicale, FranceNeuroplasticity After Proprioceptive Rehabiliation | 2027-06-15 |
| NCT06146062Assistance Publique - Hôpitaux de ParisEffects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury. | 2027-08-31 |
| NCT06930261Institut National de la Santé Et de la Recherche Médicale, FranceDopaminergic Disruption Induced by Traumatic Coma: Dopaminergic Pathways Abnormalities and Biomarkers of Recovery Using MRI and 18F-LBT-999 PET | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 98 studies in Brain Injuries, Traumatic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy of early continuous intravenous infusion of hypertonic saline solution (HSS) to improve survival and independence in daily life activities (at 6 months) of patients with traumatic brain injury at high risk of intracranial hypertension.
The criteria were revised on the registry on Nov 20, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous infusion of HSS (NaCl 20%) for 48 hours (can be prolonged during the period of intracranial hypertension)
Drug: Hypertonic saline solution
Standard of care
Continuous infusion of HSS (NaCl 20%) for 48 hours (can be prolonged during the period of intracranial hypertension)
Efficacy of early continuous of HSS
Survival : number of patients still alive
Time frame: 3 months
Efficacy of early continuous of HSS
Rate of moderate to no dependency in activities in daily living at 6 months is defined as a Barthel Index of independence in activities in daily living ≥ 61.
Time frame: 6 months
Treatment of intracranial hypertension
Evolution of blood sodium level
Time frame: 7 days
Treatment of intracranial hypertension
Evolution of blood chloride level
Time frame: 7 days
Treatment of intracranial hypertension
Evolution of solute concentration in blood plasma
Time frame: 7 days
Neurological recovery
Number of therapeutic interventions with the TIL (Therapeutic Intensity Level) scale.
Time frame: 7 days
Neurological recovery
Survival : number of patients still alive
Time frame: until 12 months
Quality of life
Score of EQ-5D-5L (5-level EuroQol-5D version) : minimum - maximal values: 1-5, higher scores mean a worse outcome.
Time frame: until 12 month
Quality of life
Rates of patient living at home, at rehabilitation centers or at hospital
Time frame: until 12 months
Anterograde amnesia
Galveston Orientation and Amnesia Test (G.O.A.T) : minimum - maximal values: 0-100, higher scores mean a better outcome.
Time frame: until 6 months
Neurocognitive functioning
Montreal Cognitive Assessment (MOCA) : minimum - maximal values: 0-30, higher scores mean a better outcome.
Time frame: 6 months
Neurological outcome
Glasgow Outcome Scale Extended (GOS-E) : minimum - maximal values: 1-8, higher scores mean a better outcome.
Time frame: 6 months
Tolerance
Rates severe hypernatremia (Na\> 160 mmol/L)
Time frame: 1 month
Tolerance
Rates of acute kidney injury
Time frame: 1 month
Tolerance
Number of thrombotic events
Time frame: 1 month
Tolerance
Number of central-pontine myelinolysis
Time frame: 1 month
Cost-effectiveness analysis
Incremental cost-effectiveness ratio
Time frame: 12 months
Genetic biomarkers
Single nucleotide polymorphism
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.
Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's planned 25 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.